CNS Pharmaceuticals stockholders approve 650,000-share increase to 2020 Equity Plan
At its September 30, 2026 annual meeting, CNS Pharmaceuticals stockholders approved an amendment raising the shares authorized under the 2020 Equity Plan by 650,000, to 765,061 shares in total. Stockholders also re-elected six directors and ratified MaloneBailey, LLP as the independent auditor for 2026, and the equity plan amendment passed with 96,953 votes for and 8,128 against.
Key points
- Equity plan amendment: 650,000-share increase, bringing the total authorized under the 2020 Plan to 765,061 shares; 96,953 votes for, 8,128 against, 35 abstentions, 563,072 broker non-votes.
- Six directors elected to serve until the 2027 annual meeting: Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin and Amy Mahery.
- MaloneBailey, LLP ratified as independent registered public accounting firm for the year ending December 31, 2026.
- Quorum reached with 668,188 shares, or 45.72% of the 1,461,449 shares outstanding as of the August 10, 2026 record date.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.